- Home
- ABBV vs BUD Comparison
ABBV vs BUD Comparison
Compare ABBV & BUD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABBV | BUD |
|---|---|---|
| Founded | 2012 | 1366 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.5B | 157.0B |
| IPO Year | 2012 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ABBV | BUD |
|---|---|---|
| Price | $262.82 | $78.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 3 |
| Target Price | ★ $253.71 | $92.00 |
| AVG Volume (30 Days) | ★ 3.7M | 1.8M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.39% | 1.33% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $61,160,000,000.00 | N/A |
| Revenue This Year | $11.87 | $8.01 |
| Revenue Next Year | $8.12 | $3.67 |
| P/E Ratio | $109.82 | ★ $23.27 |
| Revenue Growth | ★ 8.57 | N/A |
| 52 Week Low | $190.75 | $57.79 |
| 52 Week High | $267.47 | $86.60 |
Technical Indicators
Market Signals| Indicator | ABBV | BUD |
|---|---|---|
| Relative Strength Index (RSI) | 59.39 | 42.83 |
| Support Level | $242.14 | $78.02 |
| Resistance Level | $267.22 | $82.01 |
| Average True Range (ATR) | 4.70 | 0.95 |
| MACD | 1.08 | -0.24 |
| Stochastic Oscillator | 81.59 | 22.48 |
Price Performance
Historical ComparisonAbout ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the top five consumer product companies by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 acquired SABMiller.